Lingshi Tan – Founder, Chairman and CEO, dMed, China
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
The Chinese pharmaceuticals industry has reached a historic turning point in the era of innovation, filled with exciting opportunities and challenges. This new shift calls for new requirements from Chinese CROs. First, quality should be paramount. Clinical trials must be implemented in accordance with international standards at the highest quality. We partner at all stages of the conception, design, and execution of clinical trials for new drug development. dMed has emerged as a distinctive provider in this market, shouldering the inescapable responsibilities of the industry. dMed has gathered a talented and experienced team with a strong sense of ownership and collaboration to help drug developers accelerate progress and improve their success rates.
Contact
298 Xiangke Road, 3/F, 301-305, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201210, China
Tel+86 21 5090 0085
Website: http://dmedglobal.com/
Email: BD@dmedglobal.com
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in…
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth…
Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the…
BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having…
Cytiva is a global leader in bioprocessing technologies and services that support the manufacturing and research of biopharmaceuticals. China is a key market in the company’s growth story, where –…
Unlike many of its Chinese biotech peers with broad portfolios, Hua Medicine has focused intensively on developing a single product, dorzagliatin, for diabetes. As CEO Li Chen notes, this strategic…
Yoshitaka Koketsu explains Sumitomo Pharma Group’s positioning in the China market as a relatively recent market entrant with a six-product portfolio but with plentiful opportunities for further growth, particularly in…
Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a…
HKEX-main board listed Alphamab Oncology is one of China’s leading biotech success stories, having developed and marketed the world’s first subcutaneously injectable PD-L1 inhibitor. Founder, Chairman, and CEO Dr Xu…
Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA…
See our Cookie Privacy Policy Here
